高雄激素血症 中国就医指南

Hyperandrogenism is a clinical endocrine disorder characterized by excessive production or heightened peripheral activity of androgens—male sex hormones such as testosterone, androstenedione, and dehydroepiandrosterone sulfate (DHEAS)—in individuals assigned female at birth. It is not a disease in itself but rather a biochemical and phenotypic manifestation of underlying pathophysiology, most commonly associated with polycystic ovary syndrome (PCOS), which accounts for approximately 70–80% of cases. Other etiologies include non-classical congenital adrenal hyperplasia (NCAH), adrenal or ovarian tumors, Cushing’s syndrome, hyperprolactinemia, and insulin resistance–driven ovarian theca cell overstimulation. Pathogenesis involves dysregulation across the hypothalamic–pituitary–ovarian–adrenal axes, often amplified by genetic susceptibility, chronic low-grade inflammation, and adipose tissue dysfunction that enhances aromatase activity and androgen conversion. Epidemiologically, hyperandrogenism affects an estimated 5–10% of women of reproductive age globally, with prevalence rising to 12–20% in populations with high obesity rates or PCOS diagnosis. Risk factors include obesity (especially central adiposity), family history of PCOS or early-onset metabolic disease, insulin resistance, sedentary lifestyle, and exposure to endocrine-disrupting chemicals. Clinical manifestations span dermatologic (hirsutism, acne, androgenic alopecia), menstrual (oligo- or amenorrhea), metabolic (dyslipidemia, impaired glucose tolerance), and reproductive domains (anovulation, subfertility). Importantly, hyperandrogenism significantly impairs quality of life: patients report higher rates of anxiety, depression, body image distress, sexual dysfunction, and social withdrawal—often underrecognized in routine care. Untreated, it confers long-term risks including type 2 diabetes, cardiovascular disease, endometrial hyperplasia, and infertility. Early diagnosis requires integrated assessment: detailed history, physical exam (Ferriman-Gallwey score for hirsutism), serum androgen panel (total/free testosterone, DHEAS, androstenedione), AMH, pelvic ultrasound, and exclusion of malignancy or rare endocrinopathies. Management must be individualized—not solely hormone-suppressive—but centered on metabolic health, psychological support, and fertility preservation, especially within reproductive medicine departments where multidisciplinary coordination with endocrinology, dermatology, nutrition, and mental health specialists is essential.

# 高雄激素血症治疗方案与费用明细（生殖医学科）

一、非手术/保守治疗方案

适用人群：初诊、轻中度PCOS相关高雄、有生育需求或暂不耐受药物者

• •生活方式干预（饮食+运动+体重管理）：免费至200元/月（营养科随访）
• •一线药物治疗：

- 胰岛素增敏剂（二甲双胍缓释片）：25–65元/盒（30片）

• •检查费：性激素六项（280–350元）、OGTT+胰岛素释放（420–580元）、盆腔超声（220–300元）

二、手术/微创介入方案

适用人群：药物抵抗、卵巢多囊样改变显著、促排卵失败≥3周期者

• •腹腔镜下卵巢打孔术（LOD）：

- 手术费+麻醉+住院（3–5天）：12,000–18,500元

三、特殊复杂情况方案

耐药/合并严重代谢综合征/不孕年限＞5年：

• •多靶点联合（达英-35+二甲双胍+GLP-1受体激动剂）：月均药费800–2,200元
• •辅助生殖衔接（IVF前预处理）：额外增加个体化促排监测费3,500–6,000元

四、方案快速选择指南

• •预算＜5,000元/年+初诊无并发症 → 生活方式干预+短效避孕药
• •有生育诉求+药物无效 → LOD手术（性价比最优根治路径）
• •合并肥胖/糖尿病/反复流产 → 内分泌协同管理+GLP-1强化干预
• •IVF周期前优化 → 3个月药物预处理+超声动态监测（总控费≤1.2万元）